N-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide

8 trials 6 recruiting NNeurology/Psychiatry

Filter these 8 trials by condition, phase, country and more.

Open in Search →

8 Registered trials

6 Recruiting

2 Completed trials

2 Sponsors

19 Countries

Phase III

Phase II/III

Phase I/II

Phase I (Other)

Phase III: 4 Phase II/III: 2 Phase I/II: 1 Phase I (Other): 1

Indications tested

Renal cell carcinoma 3 Pancreatic neuroendocrine tumour 1 Squamous cell carcinoma of head and neck 1

Sponsors using this IMP

Exelixis Inc. 5 Merck Sharp & Dohme LLC 3

All trials

8 total

A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Ca… Recruiting

2022-501703-27-00 Phase III 14 countries Exelixis Inc.
A clinical study of belzutifan and zanzalintinib in people with advanced kidney cancer (MK-6482-034) Recruiting

2024-516993-31-00 Phase III 9 countries Merck Sharp & Dohme LLC
A Phase 2/3 clinical trial with zanzalintinib versus everolimus Recruiting

2025-521043-20-00 Phase II/III 8 countries Exelixis Inc.
A clinical study of belzutifan and zanzalintinib in people with advanced kidney cancer (MK-6482-033) Recruiting

2024-517136-21-00 Phase III 12 countries Merck Sharp & Dohme LLC
A clinical study of combination therapies in people with kidney cancer (MK-3475-03C) Recruiting

2024-516437-12-00 Phase I/II 3 countries Merck Sharp & Dohme LLC
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamo… Recruiting

2023-506308-24-00 Phase II/III 13 countries Exelixis Inc.
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety tolerability, pharmacokinetics… Ended

2023-510061-10-00 Phase I (Other) 7 countries Exelixis Inc.
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303) Ended

2024-512915-33-00 Phase III 7 countries Exelixis Inc.

Showing 1–8 of 8 trials

← All drugs A–Z